Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. more
Time Frame | DMAC | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.22% | 0.49% | -1.93% |
1-Month Return | 2.13% | -3.1% | -3.69% |
3-Month Return | 19.23% | -8.59% | 0.82% |
6-Month Return | 75.67% | -4.57% | 3.51% |
1-Year Return | 76.25% | -0.94% | 21.91% |
3-Year Return | 45.58% | 2.88% | 24.73% |
5-Year Return | 17.65% | 35.84% | 78.4% |
10-Year Return | 437.76% | 98.8% | 187.28% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 21.00K | 21.00K | 24.00K | 25.00K | 30.00K | [{"date":"2019-12-31","value":70,"profit":true},{"date":"2020-12-31","value":70,"profit":true},{"date":"2021-12-31","value":80,"profit":true},{"date":"2022-12-31","value":83.33,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (21.00K) | (21.00K) | (24.00K) | (25.00K) | (30.00K) | [{"date":"2019-12-31","value":-2100000,"profit":false},{"date":"2020-12-31","value":-2100000,"profit":false},{"date":"2021-12-31","value":-2400000,"profit":false},{"date":"2022-12-31","value":-2500000,"profit":false},{"date":"2023-12-31","value":-3000000,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 10.74M | 12.49M | 13.65M | 14.00M | 21.27M | [{"date":"2019-12-31","value":50.49,"profit":true},{"date":"2020-12-31","value":58.75,"profit":true},{"date":"2021-12-31","value":64.17,"profit":true},{"date":"2022-12-31","value":65.83,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (11.59M) | (12.70M) | (13.65M) | (14.00M) | (21.27M) | [{"date":"2019-12-31","value":-1159300000,"profit":false},{"date":"2020-12-31","value":-1269900000,"profit":false},{"date":"2021-12-31","value":-1364600000,"profit":false},{"date":"2022-12-31","value":-1400100000,"profit":false},{"date":"2023-12-31","value":-2126700000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (10.62M) | (12.27M) | (13.56M) | (13.65M) | (19.34M) | [{"date":"2019-12-31","value":-1061800000,"profit":false},{"date":"2020-12-31","value":-1226500000,"profit":false},{"date":"2021-12-31","value":-1356400000,"profit":false},{"date":"2022-12-31","value":-1364800000,"profit":false},{"date":"2023-12-31","value":-1933800000,"profit":false}] |
Income Taxes | 31.00K | 27.00K | 28.00K | 28.00K | 43.00K | [{"date":"2019-12-31","value":72.09,"profit":true},{"date":"2020-12-31","value":62.79,"profit":true},{"date":"2021-12-31","value":65.12,"profit":true},{"date":"2022-12-31","value":65.12,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (10.65M) | (12.29M) | (13.59M) | (13.68M) | (17.97M) | [{"date":"2019-12-31","value":-1064900000,"profit":false},{"date":"2020-12-31","value":-1229200000,"profit":false},{"date":"2021-12-31","value":-1359200000,"profit":false},{"date":"2022-12-31","value":-1367600000,"profit":false},{"date":"2023-12-31","value":-1797100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (10.65M) | (12.29M) | (13.59M) | (13.68M) | (19.38M) | [{"date":"2019-12-31","value":-1064900000,"profit":false},{"date":"2020-12-31","value":-1229200000,"profit":false},{"date":"2021-12-31","value":-1359200000,"profit":false},{"date":"2022-12-31","value":-1367600000,"profit":false},{"date":"2023-12-31","value":-1938100000,"profit":false}] |
EPS (Diluted) | (0.89) | (0.78) | (0.64) | (0.52) | (0.62) | [{"date":"2019-12-31","value":-89,"profit":false},{"date":"2020-12-31","value":-78,"profit":false},{"date":"2021-12-31","value":-64,"profit":false},{"date":"2022-12-31","value":-52,"profit":false},{"date":"2023-12-31","value":-62,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
DMAC | |
---|---|
Cash Ratio | 11.68 |
Current Ratio | 11.81 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
DMAC | |
---|---|
ROA (LTM) | -23.54% |
ROE (LTM) | -35.18% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
DMAC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.09 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.91 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
DMAC | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 4.70 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
DiaMedica Therapeutics Inc (DMAC) share price today is $4.97
Yes, Indians can buy shares of DiaMedica Therapeutics Inc (DMAC) on Vested. To buy DiaMedica Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DMAC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of DiaMedica Therapeutics Inc (DMAC) via the Vested app. You can start investing in DiaMedica Therapeutics Inc (DMAC) with a minimum investment of $1.
You can invest in shares of DiaMedica Therapeutics Inc (DMAC) via Vested in three simple steps:
The 52-week high price of DiaMedica Therapeutics Inc (DMAC) is $6.41. The 52-week low price of DiaMedica Therapeutics Inc (DMAC) is $2.14.
The price-to-earnings (P/E) ratio of DiaMedica Therapeutics Inc (DMAC) is
The price-to-book (P/B) ratio of DiaMedica Therapeutics Inc (DMAC) is 4.70
The dividend yield of DiaMedica Therapeutics Inc (DMAC) is 0.00%
The market capitalization of DiaMedica Therapeutics Inc (DMAC) is $213.31M
The stock symbol (or ticker) of DiaMedica Therapeutics Inc is DMAC